The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ADAMs as new therapeutic targets for triple-negative breast cancer.
M. Mullooly
No relevant relationships to disclose
P. M. McGowan
No relevant relationships to disclose
S. U. Sukor
No relevant relationships to disclose
S. F. Madden
No relevant relationships to disclose
E. McDermott
No relevant relationships to disclose
J. Crown
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
N. O'Donovan
No relevant relationships to disclose
M. J. Duffy
No relevant relationships to disclose